% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • fludyspnea fludyspnea May 8, 2014 10:57 PM Flag

    Varlilumab Trial Change

    Trial just updated today. Three main changes:

    1) Hematologic Malignancies expanded to include any T-cell Malignancy (previously B-cell only).

    2) The B-cell Malignancy enrollment of the dose escalation phase is now closed

    3) Mount Sinai Medical Center in New York has been added as a 9th site.

    The addition of a new center with a dedicated immunotherapy program is definitely a positive. Joshua Brody, MD, who's speciality is lymphoma immunotherapy will be the primary investigator. I doubt a new center would be added if preliminary results were not looking promising.

    Significance of expansion to T-cell malignancies is uncertain. T-cell lymphomas are only about 15% of lymphomas so would be harder to enroll and likely why these were not included initially. My guess is that with the possible success being seen in B-cell malignancies it was elected to include the T-cell malignancies at this point.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
7.26-0.12(-1.63%)Feb 5 4:00 PMEST